药物发现
连接器
计算生物学
计算机科学
药品
生物信息学
纳米技术
生物
材料科学
药理学
操作系统
作者
Viktoriya Ivasiv,Claudia Albertini,Ana Elisa Gonçalves,Michele Rossi,María Laura Bolognesi
标识
DOI:10.2174/1568026619666190619115735
摘要
Molecular hybridization is a well-exploited medicinal chemistry strategy that aims to combine two molecules (or parts of them) in a new, single chemical entity. Recently, it has been recognized as an effective approach to design ligands able to modulate multiple targets of interest. Hybrid compounds can be obtained by linking (presence of a linker) or framework integration (merging or fusing) strategies. Although very promising to combat the multifactorial nature of complex diseases, the development of molecular hybrids faces the critical issues of selecting the right target combination and the achievement of a balanced activity towards them, while maintaining drug-like-properties. In this review, we present recent case histories from our own research group that demonstrate why and how molecular hybridization can be carried out to address the challenges of multitarget drug discovery in two therapeutic areas that are Alzheimer’s and parasitic diseases. Selected examples spanning from linker- to fragment- based hybrids will allow to discuss issues and consequences relevant to drug design.
科研通智能强力驱动
Strongly Powered by AbleSci AI